Literature DB >> 32038935

Combination immune checkpoint inhibitors with platinum-based chemotherapy in advanced non-small cell lung cancer: what's known and what's next.

Tao Jiang1,2, Caicun Zhou1, Jie Hu2, Yuanlin Song2.   

Abstract

Entities:  

Year:  2019        PMID： 32038935      PMCID： PMC6987347          DOI： 10.21037/tlcr.2019.11.10

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  13 in total

1.  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Authors:  Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer.

Authors:  Sha Zhao; Shengxiang Ren; Tao Jiang; Bo Zhu; Xuefei Li; Chao Zhao; Yijun Jia; Jinpeng Shi; Limin Zhang; Xiaozhen Liu; Meng Qiao; Xiaoxia Chen; Chunxia Su; Hui Yu; Caicun Zhou; Jun Zhang; D Ross Camidge; Fred R Hirsch
Journal:  Cancer Immunol Res       Date:  2019-02-12       Impact factor: 11.151

Review 3.  Cancer immunotherapy using checkpoint blockade.

Authors:  Antoni Ribas; Jedd D Wolchok
Journal:  Science       Date:  2018-03-22       Impact factor: 47.728

Review 4.  Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.

Authors:  Shetal A Patel; Andy J Minn
Journal:  Immunity       Date:  2018-03-20       Impact factor: 31.745

Review 5.  Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.

Authors:  K M Heinhuis; W Ros; M Kok; N Steeghs; J H Beijnen; J H M Schellens
Journal:  Ann Oncol       Date:  2019-02-01       Impact factor: 32.976

6.  Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Authors:  Luis Paz-Ares; Alexander Luft; David Vicente; Ali Tafreshi; Mahmut Gümüş; Julien Mazières; Barbara Hermes; Filiz Çay Şenler; Tibor Csőszi; Andrea Fülöp; Jerónimo Rodríguez-Cid; Jonathan Wilson; Shunichi Sugawara; Terufumi Kato; Ki Hyeong Lee; Ying Cheng; Silvia Novello; Balazs Halmos; Xiaodong Li; Gregory M Lubiniecki; Bilal Piperdi; Dariusz M Kowalski
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

7.  Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.

Authors:  Howard West; Michael McCleod; Maen Hussein; Alessandro Morabito; Achim Rittmeyer; Henry J Conter; Hans-Georg Kopp; Davey Daniel; Steven McCune; Tarek Mekhail; Alona Zer; Niels Reinmuth; Ahad Sadiq; Alan Sandler; Wei Lin; Tania Ochi Lohmann; Venice Archer; Lijia Wang; Marcin Kowanetz; Federico Cappuzzo
Journal:  Lancet Oncol       Date:  2019-05-20       Impact factor: 41.316

Review 8.  Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors.

Authors:  Sanjeevani Arora; Rodion Velichinskii; Randy W Lesh; Usman Ali; Michal Kubiak; Pranshu Bansal; Hossein Borghaei; Martin J Edelman; Yanis Boumber
Journal:  Adv Ther       Date:  2019-08-13       Impact factor: 3.845

9.  Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Authors:  Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck
Journal:  N Engl J Med       Date:  2018-06-04       Impact factor: 91.245

Review 10.  The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer.

Authors:  Jia Li Low; Robert J Walsh; Yvonne Ang; Gloria Chan; Ross A Soo
Journal:  Ther Adv Med Oncol       Date:  2019-08-28       Impact factor: 8.168
View more
  5 in total

1.  Atezolizumab plus carboplatin and nab-paclitaxel versus carboplatin and nab-paclitaxel as treatments for Chinese, treatment-naïve, stage IV, non-squamous, non-small-cell lung cancer patients: A retrospective analysis.

Authors:  Yingkai Chen; Shizhou Kang; Ming Yan
Journal:  Pharmacol Res Perspect       Date:  2022-06

2.  IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.

Authors:  Stephen P Hack; Wendy Verret; Sohail Mulla; Bo Liu; Yulei Wang; Teresa Macarulla; Zhenggang Ren; Anthony B El-Khoueiry; Andrew X Zhu
Journal:  Ther Adv Med Oncol       Date:  2021-07-31       Impact factor: 8.168

3.  Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.

Authors:  Yanjun Xu; Hui Li; Zhiyu Huang; Kaiyan Chen; Xiaoqing Yu; Jiamin Sheng; Han-Han Zhang; Yun Fan
Journal:  Transl Lung Cancer Res       Date:  2020-12

4.  Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience.

Authors:  Xinqing Lin; Haiyi Deng; Likun Chen; Di Wu; Xiaobo Chen; Yilin Yang; Tao Chen; Xiaohong Xie; Zhanhong Xie; Ming Liu; Ming Ouyang; Yinyin Qin; Shiyue Li; Nanshan Zhong; Jeffrey P Gregg; Nobuyuki Horita; Yong Song; Chengzhi Zhou
Journal:  Transl Lung Cancer Res       Date:  2021-01

5.  Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non-Small Cell Lung Cancer.

Authors:  Shun Lu; Yan Yu; Gisoo Barnes; Xiusong Qiu; Yuanyuan Bao; Boxiong Tang
Journal:  Cancer J       Date:  2022 Mar-Apr 01       Impact factor: 3.360
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.